hVIVO has signed a £13.6m contract with a US biotechnology client to test its antiviral product in a Phase IIa study, using hVIVO’s respiratory syncytial virus (RSV) Human Challenge Study Model. The study is expected to commence in Q3/Q4 2023, with revenues to be recognised in 2023 and 2024. Not only is this study the largest RSV study contracted to date for which hVIVO should have received a non-refundable upfront reservation fee of c.£2m, but it builds revenue visibility into FY 2023. Moreover ....
10 Nov 2022
hVIVO - £13.6m RSV human challenge contract
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
hVIVO - £13.6m RSV human challenge contract
hVIVO plc (HVO:LON) | 26.5 -0.2 (-2.8%) | Mkt Cap: 180.3m
- Published:
10 Nov 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
4
hVIVO has signed a £13.6m contract with a US biotechnology client to test its antiviral product in a Phase IIa study, using hVIVO’s respiratory syncytial virus (RSV) Human Challenge Study Model. The study is expected to commence in Q3/Q4 2023, with revenues to be recognised in 2023 and 2024. Not only is this study the largest RSV study contracted to date for which hVIVO should have received a non-refundable upfront reservation fee of c.£2m, but it builds revenue visibility into FY 2023. Moreover ....